Offering no clear reason for formulary choices, or why a purportedly value-based formulary option is not being adopted is not evidence-based. Nor is it evidence-based to give an absolute “no” to high-priced therapies in spite of their comparative effectiveness.
U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions
